1. Introduction {#S1}
===============

Female genital tuberculosis (GTB) is typically detected in 18-19% of Indian women of the reproductive age groups as per a study conducted in 2008, which increased to 19-30% in 2015, affecting the pelvic organs by different routes, often during investigating for infertility (1). It is difficult to find out the actual incidence of GTB as many cases are asymptomatic and diagnosed incidentally. Although the frank Extra-pulmonary tuberculosis (EPTB) in the form of GTB is prevalent in Southeast Asia, the mere presence of tubercular bacilli in the genital tract which may otherwise be called as latent female genital tuberculosis (FGTB)infestation is becoming more and more important as a causative factor for reproductive failure (2, 3). Implantation is one of the important early stages for the initiation of successful pregnancy that involves formation of matured embryo and receptive endometrium. An immature endometrium becomes non-receptive that does not allow implantation and rejects the implanted early embryo from its nidation site. Endometrial development may be affected by tubercular infestation that invites harmful cytokines in the decidua. It has been observed that sub-endometrial vascularity decreases due to the involvement of basal layer of the endometrium in latent FGTB as evident by pioneer work (4). The possibility of vascular micro thrombus formation following the tubercular assault of endometrium leads to implantation failure and miscarriage. Tuberculous endometritis is found in 80% of patients, whereas tuberculous salpingitis and oophoritis are seen in around 8% of them (5, 6). However, according to few, the endometrium appears to be the most commonly involved site in EPTB (7). The incidence of pregnancy and live birth following is seen to be quite low and the possibility of ectopic pregnancy increases or results in loss of pregnancy (8, 9).

The purpose of this study was to detect the underlying causes of recurrent pregnancy loss (RPL) in addition to the causes like uterine cavity defects, thrombophilia, chromosomal abnormalities, etc., so far mentioned in literature.

2. Materials and Methods {#S2}
========================

A total of 317 woman aged range between 20-45 yr old who were referred to Department of Reproductive Medicine at Calcutta Fertility Mission, over a period of 60 months (January 2014 to December 2018) were enrolled in this observational study. The inclusion criteria were woman who had two or more recurrent pregnancy losses, women who had diagnosed uterine malformations, chromosomal defects, thrombophilia etc. were excluded.

Women were divided into three groups: Groups A, B, and C in which Group A (only TB-PCR Positive, n = 109) included patients with RPL who had only latent FGT Bas the etiological factor of the losses among the factors screened in this study. Group B (TB-PCR Positive, n = 134) consisted of women with recurrent miscarriage who were found to have tubercular bacilli along with any of the other factors as etiology. Group C (TB-PCR-Negative, n = 74) included patients who did not have any tubercular infestation but some other etiology for RPL. They had undergone routine tests for the same along with the PCR test with an endometrial aspirate.

Ethical consideration
---------------------

The Ethical Committee of Calcutta Fertility Mission has given clearance for the retrospective study of a prospective database on 02/01/2019 (code: CFM/2019/024). Written informed consent has been obtained from all women who participated in the study.

Statistical analysis
--------------------

The obtained results were analyzed using SPSS Statistics software (Statistical Package for the Social Sciences, version 17.0, SPSS Inc, Chicago, Illinois, USA). The comparison between groups was evaluated using the Pearson\'s Chi-Square test and Fischer\'s exact test. A P value of $<$0.05 was considered to be statistically significant.

3. Results {#S3}
==========

A total of 317 patients included in this study were divided into three groups as follows: Group A consisted of 109 patients (34.4%), Group B included 134 patients (42.3%), and Group C had 74 patients (23.3%). Both the age of the patient and their obstetric score did not have any statistical significance in the present study. 76.6% had latent FGTB detected by PCR test (TB-PCR positive). On a descriptive statistical analysis, it was observed that the latent FGTB was an important cause of RPL irrespective of association with the other etiological factors, age, or the obstetric score (Tables I, II). Other causes of RPL like overt diabetes, hypothyroidism or hyperthyroidism, hyperandrogenism, hyperprolactinemia, low ovarian reserve, hyperhomocysteinemia, antiphospholipid antibody syndrome, and toxoplasmosis were analyzed (Table III).

Both impaired Glucose Tolerance Test and abnormal levels of TSH were not seen to be a statistically significant cause of RPL (p = 0.618). Though we found that the patients suffering from RPL have increased testosterone or decreased AMH levels with or without associated latent FGTB, these parameters were not statistically significant (p = 0.377). Even increased levels of Serum Homocysteine was not found to have any statistical (p = 0.496).

Group C participants who had hyperprolactinemia as the only etiology of RPL were more than the participants of Group B who had increased levels of prolactin associated with latent FGTB. In both groups, B and C, toxoplasmosis was seen to be a statistically significant factor for causing RPL. Anti-cardiolipin antibodies and Lupus anticoagulant time also did not have any statistical significance as the RPL etiology. Among these three groups the clinical pregnancy rate (CPR), live birth rate (LBR), and miscarriage rate have been calculated and compared. CPR within next 12 months, after taking anti-tubercular drugs for six months, was more in Group B when compared to Groups A and C and was statistically significant. Also, LBR and miscarriage rate was statistically significant (Table IV). The rate of miscarriage was high in both Groups A and B compared to Group C.

###### 

Age of women in groups

  ----------------------------------------------------- ------------- ------------- ------------- ------------- -------
                                                                                                                
  **Age**                                               **Group**     **Total**     **P-value**                 
                                                        **Group A**   **Group B**   **Group C**                 0.060
  20-25                                                 27 (24.77)    16 (11.94)    17 (22.97)    60 (18.93)    
  26-30                                                 40 (36.7)     59 (44.03)    19 (25.68)    118 (37.22)   
  31-35                                                 29 (26.61)    37 (27.61)    25 (33.78)    91 (28.71)    
  36-40                                                 9 (8.26)      19 (14.18)    12 (16.22)    40 (12.62)    
  41-45                                                 4 (3.67)      3 (2.24)      1 (1.35)      8 (2.52)      
                                                                                                                
  Data presented as n (%); Pearson\'s Chi-Square test                                                           
  ----------------------------------------------------- ------------- ------------- ------------- ------------- -------

###### 

Obstetric score of participants

  --------------------- ------------- ------------- ------------- ------------- -------
                                                                                
  **Obstetric score**   **Group**     **Total**     **P-value**                 
                        **Group A**   **Group B**   **Group C**                 
  P (0+2)               23 (21.1)     43 (32.09)    29 (39.19)    95 (29.97)    0.064
  P (0+3)               60 (55.05)    59 (44.03)    27 (36.49)    146 (46.06)   
  P (0+4)               11 (10.09)    13 (9.7)      5 (6.76)      29 (9.15)     
  P (0+5)               2 (1.83)      9 (6.72)      1 (1.35)      12 (3.79)     
  P (0+6)               4 (3.67)      1 (0.75)      1 (1.35)      6 (1.89)      
  P (0+7)               1 (0.92)      1 (0.75)      3 (4.05)      5 (1.58)      
  P (1+2)               3 (2.75)      3 (2.24)      3 (4.05)      9 (2.84)      
  P (1+3)               2 (1.83)      4 (2.99)      2 (2.7)       8 (2.52)      
  P (1+4)               3 (2.75)      0 (0)         1 (1.35)      4 (1.26)      
  P (2+2)               0 (0)         1 (0.75)      2 (2.7)       3 (0.95)      
  --------------------- ------------- ------------- ------------- ------------- -------

###### 

Participants etiology

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- ------------- ------------- -------------
                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                     **Group A**   **Group B**   **Group C**   **P-value**
  Pcr/Mtb                                                                                                                                                                                                                                                                            109 (100)     134 (100)     0 (0)         $<$0.001
  Gtt                                                                                                                                                                                                                                                                                0 (0)         42 (31.34)    14 (18.92)    0.053
  Tsh                                                                                                                                                                                                                                                                                0 (0)         20 (14.93)    13 (17.57)    0.618
  Toxo                                                                                                                                                                                                                                                                               0 (0)         4 (2.99)      12 (16.22)    0.001
  Aca                                                                                                                                                                                                                                                                                0 (0)         9 (6.72)      3 (4.05)      0.545
  La                                                                                                                                                                                                                                                                                 0 (0)         5 (3.73)      5 (6.76)      0.339
  St                                                                                                                                                                                                                                                                                 0 (0)         32 (23.88)    16 (21.62)    0.711
  Amh                                                                                                                                                                                                                                                                                0 (0)         34 (25.37)    23 (31.08)    0.377
  Prl                                                                                                                                                                                                                                                                                0 (0)         15 (11.19)    20 (27.03)    0.003
  Homocysteine                                                                                                                                                                                                                                                                       0 (0)         7 (5.22)      2 (2.7)       0.496
                                                                                                                                                                                                                                                                                                                               
  Data presented as n (%); Fischer\'s exact test                                                                                                                                                                                                                                                                               
  PCR/MTB: Polymerase chain reaction/ mycobacterium tuberculosis; GTT: Glucose tolerance test; TSH: Thyroid stimulating hormone; TOXO: Toxoplasmosis; ACA: Anti-cardiolipin antibody; LA: Lupus anticoagulant; ST: Serum testosterone; AMH: Anti-Mullerian hormone; PRL: Prolactin                                             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- ------------- ------------- -------------

###### 

Clinical pregnancy rate, live birth rate, and miscarriage rate in groups

  ----------------------------------------------------- ------------- ------------- ------------- ------------- -------------
                                                                                                                
                                                        **Group A**   **Group B**   **Group C**   **Total**     **P-value**
  Clinical pregnancy                                    32 (29.36)    63 (47.01)    16 (21.62)    111 (35.02)   $<$0.001
  Live birth                                            12 (37.5)     22 (34.92)    12 (75)       46 (41.44)    0.013
  Miscarriage                                           20 (62.5)     39 (61.9)     3 (18.75)     62 (55.86)    0.005
                                                                                                                
  Data presented as n (%); Pearson\'s Chi-Square test                                                           
  ----------------------------------------------------- ------------- ------------- ------------- ------------- -------------

4. Discussion {#S4}
=============

Repeated miscarriage appears to be a curse in a woman\'s reproductive career. It becomes difficult to form a work-up to detect the cause of RPL in the early months as a continuation of pregnancy involves many factors. The factors may be genetic factors, anatomical causes (uterine cavity defect), hormonal causes, or miscellaneous like infections and immunological factors. In this study, uterine defects and ectopic pregnancy have been excluded, and a focus is placed on other factors. Routine tests which involve factors mentioned previously have been performed in all patients and one new test included in the miscellaneous group has been performed to detect a tubercular infestation of the endometrium as a causative factor of RPL (10). It has been observed that quite a large number of cases of RPL are affected with latent FGTB or a tubercular infestation of the endometrium as a sole or strongly associated factor for the development of such an unfortunate situation.

The prevalence of FGTB in developing countries is high among infertile patients with tubal factor involvement, involving almost 90%; with 82.9% having endometrial involvement too (11).

It has been seen that 92.3% of infertile women without tubal defects who had been treated with anti-tubercular drugs (ATD) based on a positive endometrial aspirate TB-PCR test had spontaneous conception within 12 months of treatment (12). Similarly, in our study, patients with RPL with secondary infertility who otherwise had no other demonstrable cause of pregnancy loss other than latent FGTB, 29.36% of patients had conceived spontaneously during or within 12 months of ATD administration. 47.01% of the patients in our study had spontaneous conception after a treatment with ATD and any other associated etiological factor for RPL. Anti-tubercular treatment (ATT) should be given in early disease if the patient had raised ESR ($\geq$ 20 mm/first hr), Mantoux test positive (induration $\geq$ 10 mm), hysterosalpingography picture or ultrasonological picture suggestive of GTB. Hence the chances of pregnancy can be enhanced and irreversible damage to the endometrium and especially fallopian tubes can be prevented and there will be increased chances of conception (13).

In our study, 16.22% of patients had toxoplasmosis as the sole factor for RPL, whereas 2.99 % of them had toxoplasmosis associated with latent FGTB, which complies with other studies (14, 15). Hyperprolactinemia in initial stage of follicular growth may hinder secretion of progesterone which eventually result in luteal phase defects and RPL, and the treatment may reduce the rate of miscarriage in a subsequent pregnancy in these women which is similar to our findings (16).

In recent studies, only 36.7% patients with GTB have been noted to achieve pregnancy after ATD treatment which concludes that the outcome of infertility in GTB is not very optimistic and IVF-ET need to be considered in such cases (8). In this study, CPR and LBR were relatively better being 29.36% and 37.5%, respectively, in Group A and 47.01% and 34.92%, respectively, in Group B.

In our study, the rate of miscarriage in an ongoing pregnancy was high in both Group A (62.5%) and Group B (61.9%); compared to 18.75% in Group C that correlates with other studies (17) which conclude that in women with GTB, the CPR per cycle was low and spontaneous abortion was high. Women with GTB were seen to represent a less favorable group within other tubal factor patients when treated with IVF-ET.

Low-grade inflammation might lead to minimal structural and functional alteration of the pelvic organs as observed in Mycobacterium tuberculosis infestation. Mycobacterium colonization in the endometrium, what has been mentioned as the tubercular infestation, may be a cause of reproductive failure too (3). An important cause of implantation failure is the immunological factor and improving endometrial receptivity in the course of fertility management by improving success rates. The evaluation of implantation markers is necessary to detect occult endometrial assault. The most offensive cytokine for the loss of pregnancy is TNF-α. TNF-α, and anti-cardiolipin antibody levels are seen to be potential diagnostic markers and they exhibit significant role in prognosis of RPL patients (18). An increased prevalence of IFN-γ has been shown in endometrial aspirate in TBPCR positive cases. Hence, IFNγ showed a possibility to become an important clinical indicator of endometrial hostility followed by IL2 and on treatment by ATD improved reproductive outcome indicating the ill effect is reversible, as in contrast to tubercular infection (3). Key endometrial genes expression along with gene or stem cell-based therapies may be incorporated to improve implantation (19). Tubercular infestation or LGTB as per our study appears to be a very important cause in patients with apparently unexplained RPL following routine tests. It appears that the exclusion of tubercular infestation should be one of the most relevant investigations in cases of RPL.
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